 |
|
|
| |
48 Weeks of Peginterferon Alfa-2a/Ribavirin Improves SVR24 and Decreases Relapse across HCV Genotype 2/3 Patient Subgroups Not Achieving a Rapid Virological Response: N-CORE Study
|
| |
| |
Reported by Jules Levin
EASL 2013 Amsterdam April 24-28
T. Berg,1 M.L. Shiffman,2 S. Zeuzem,3 C.P. Berg,4 C. de Figueiredo-Mendes,5 G.J. Dore,6 M. Lucia Ferraz,7 M. Cassia Mendes-Correa,8 M. Patelli Lima,9 E. Parise,7 A.M. Perez Rios,10 T. Reuter,11 A.J. Sanyal,12 S.D. Shafran,13 M. Hohmann,14 F. Tatsch,15 H. Cheinquer16; on behalf of the N-CORE study group
1Hepatology Section, Department of Gastroenterology and Rheumatology, Universitätsklinikum Leipzig, Leipzig, Germany; 2Liver Institute of Virginia, Bon Secours Health System, Richmond and Newport News, VA, USA; 3Department of Medicine 1, J.W. Goethe University Hospital, Frankfurt, Germany; 4Department of Internal Medicine 1, University Hospital Tubingen, Tubingen, Germany; 5Santa Casa da Misericordia do Rio de Janeiro, Hospital Geral, Brazil; 6Kirby Institute, The University of New South Wales, Darlinghurst, NSW, Australia; 7Department of Gastroenterology, Escola Paulista de Medicina, UNIFESP, Sao Paulo, Brazil; 8Infectious Diseases Research Unit, ABC Foundation Medical School, Sao Paulo Infectious Diseases Research Unit, Brazil; 9Medical Sciences, Pontifícia Universidade Catolica de Campinas, Sao Paulo, Brazil; 10Centro de Investigacion Farmacéutica Especializada, Guadalajara, JAL, Mexico; 11Centre for Infectious Diseases, Universidade Federal do Espírito Santo, Brazil; 12Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University School of Medicine, Richmond, VA, USA; 13Division of Infectious Diseases, University of Alberta, Edmonton, AB, Canada; 14IST GmbH, Mannheim, Germany; 15F. Hoffmann-La Roche Ltd, Basel, Switzerland; 16Department of Gastroenterology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
|
| |
|
|
|
|
|
